Clinical Trials Sponsored by Akston Biosciences Corporation

Total 815 results

University Medical Center Groningen
Akston Biosciences Corporation

Completed

Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study (ACT)

Covid19

Netherlands
Venn Biosciences Corporation

Completed

Non-invasive Identification of Colorectal Cancer and Adenomas in Early Stages (NICE)

Colorectal Cancer

United States
Venn Biosciences Corporation

Completed

Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy (VOCAL)

Ovarian Cancer | Adnexal Mass | Pelvic Mass

Philippines, United States, Malaysia, Australia
Graviton Bioscience Corporation

Completed

Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects

Phase 1

United States
Alliancells Bioscience Corporation Limited

Unknown

Safety and Efficacy Study of Umbilical Mesenchymal Stem Cells for Liver Cirrhosis (LC)

Liver Cirrhosis

China
Alliancells Bioscience Corporation Limited

Unknown

Safety and Efficacy Study of Umbilical Cord-Derived Mesenchymal Stem Cells for Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

China
Incyte BioSciences France

Completed

Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)

Chronic Myeloid Leukemia

France
Incyte Biosciences Benelux

Completed

Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium

Chronic Myeloid Leukemia | CML | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Ph+ ALL

Belgium
Assembly Biosciences
Arbutus Biopharma Corporation

Terminated

A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection

Chronic Hepatitis B

Australia, Canada, Bulgaria, New Zealand
Incyte Biosciences UK

Completed

CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Blastic Phase Chronic Myelogenous Leukemia

United Kingdom, Ireland
Perle Bioscience, Inc.
Syreon Corporation

Withdrawn

The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients (IIT)

Type 1 Diabetes
Incyte Biosciences Japan GK

Not yet recruiting

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease

Chronic Graft-versus-host-disease
Incyte Biosciences International Sàrl

Recruiting

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States, Taiwan, Italy, Korea, Republic of, Spain, France, Portugal, Germany, Poland, Canada, Georgia, Greece, Netherlands, Belgium
Incyte Biosciences International Sàrl

Recruiting

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

Lymphoma | Acute Myeloid Leukemia | Leukemia | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Solid Tumors | Chronic Phase Chronic Myeloid Leukemia | Accelerated Phase Chronic Myeloid Leukemia | Blast Phase Chronic Myeloid Leukemia

Spain, Italy, France, Germany, United Kingdom, Belgium, Sweden, Denmark, Netherlands
Incyte Biosciences International Sàrl

Withdrawn

INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Advanced Malignancies | Metastatic Head and Neck Squamous Cell Carcinoma

United States
Qure Healthcare, LLC
Venn Biosciences Corporation

Withdrawn

Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn Test

Non Small Cell Lung Cancer
Incyte Biosciences Japan GK

Completed

A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

Japan
Incyte Biosciences International Sàrl

Completed

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Metastatic Cancer | Advanced Malignancies

United States, Belgium, Australia, Spain
Incyte Biosciences International Sàrl

Completed

A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors

Metastatic Cancer | Advanced Malignancies

United States, United Kingdom, Spain, Switzerland
Incyte Biosciences Japan GK

Recruiting

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (J-MIND)

Diffuse Large B-cell Lymphoma | Non Hodgkins Lymphoma

Japan
Incyte Biosciences International Sàrl

Completed

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Advanced Malignancies

United States
Incyte Biosciences International Sàrl

Terminated

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Metastatic Cancer | Advanced Malignancies

United States
Incyte Biosciences International Sàrl

Completed

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Cervical Cancer | Hepatocellular Carcinoma | Esophageal Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer (NSCLC) | Urothelial Carcinoma | Merkel Cell Carcinoma | Diffuse Large B-cell Lymphoma | Triple-negative Breast Cancer | Renal Cell Carcinoma (RCC) | Small Cell Lung Cancer (SCLC) | Squamous... and other conditions

United States
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation

Completed

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States, France, Italy, United Kingdom
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation

Completed

A Study of AC220 Given After Transplant in Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
Daiichi Sankyo, Inc.
Ambit Biosciences Corporation

Completed

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
Incyte Biosciences International Sàrl

Withdrawn

A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"

BCR-ABL Positive Acute Lymphoblastic Leukemia

Germany, France, Czechia
Incyte Biosciences Japan GK

Completed

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

Lymphoma

Japan
Incyte Biosciences Japan GK

Terminated

To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550

Solid Tumors

Japan
Incyte Biosciences Japan GK

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707

Healthy Participants

Japan
Incyte Biosciences International Sàrl

Completed

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

Metastatic Cancer | Advanced Malignancies

United States
Senda Biosciences
Boston Children's Hospital

Withdrawn

Comparison of Microbiome Composition and Biomarkers in Pharmaco Resistant and Pharmaco-Sensitive Epilepsy

Epilepsy in Children | Pharmaco-Resistant Epilepsy

United States
Freya Biosciences ApS
Boston IVF

Recruiting

Vaginal Microbiome and IVF Pregnancy Outcome

Vaginal Flora Imbalance

United States
Boston Scientific Corporation
Guidant Corporation

Terminated

MODULA Modul 7 VRR

Atrial Fibrillation

Germany
Boston Scientific Corporation
EKOS Corporation

Completed

ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism (ULTIMA)

Submassive Pulmonary Embolism

Germany, Switzerland
Boston Scientific Corporation
EKOS Corporation

Completed

Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism (OPTALYSE PE)

Pulmonary Embolism and Thrombosis

United States, United Kingdom
Boston Scientific Corporation
EKOS Corporation

Completed

Submassive and Massive Pulmonary Embolism Treatment With Ultrasound Accelerated Thrombolysis Therapy (SEATTLE II)

Pulmonary Embolism | Acute Pulmonary Embolism | Pulmonary Thromboembolism | Massive Pulmonary Embolism | Sub-massive Pulmonary Embolism

United States
Boston Scientific Corporation
Guidant Corporation

Completed

MODULA Modul 5 BEAT-HF

Heart Failure

Germany
Boston Scientific Corporation
Guidant Corporation

Terminated

MODULA-Study: Modul 10: Benefit of CRT-Therapy in CRT-Patients With QRS-Complex of 120 - 150 Ms

Heart Failure

Germany
Guidant Corporation
Boston Scientific Corporation

Completed

Cognis and Teligen 100 HE and Reliance Quadripolar Defibrillation Lead (4-Site) Field Following (Cogent-4)

Heart Failure | Ventricular Tachycardia, Ventricular Fibrillation

Israel, Denmark
Senda Biosciences
Boston Children's Hospital

Withdrawn

Microbiome Composition and Biomarker Discovery in Refractory Pediatric Epilepsy

Epilepsy

United States
Boston Scientific Corporation
Guidant Corporation

Completed

Septal - Success Rate and Clinical Outcome of Septal Implant of Ventricular Defibrillation Lead

Ventricular Fibrillation | Ventricular Tachycardia

France
Boston Scientific Corporation
Guidant Corporation

Completed

Shockless Implant Evaluation (SIMPLE)

Ventricular Fibrillation | Ventricular Tachycardia

Germany, Spain, Canada, Israel, Netherlands, France, Finland, United Kingdom, Austria, Malaysia, Thailand, Hong Kong, Sweden, Hungary, Australia, Czechia, Norway, Poland
Boston Scientific Corporation
Guidant Corporation

Completed

Feature Assessment Study for Indications Based Programming (FASt-IBP)

Heart Failure | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Flutter

Germany, Spain, Switzerland, China, Austria, Belgium, France, Greece, Latvia, Netherlands, Slovakia
Boston Scientific Corporation
Guidant Corporation

Completed

Japanese Assessment of Indication Based Programming (JASMINE)

Heart Failure | Arrhythmias, Cardiac

Japan
Boston Scientific Corporation
Guidant Corporation

Completed

Quick ICD Study: Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary ? (Quick ICD)

Cardiac Arrest

Germany
Boston Scientific Corporation
EKOS Corporation

Withdrawn

Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)

Coronary Artery Disease | Atherosclerosis | Peripheral Artery Disease | Chronic Total Occlusion

United States
Boston Scientific Corporation
EKOS Corporation

Completed

Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System (ACCESS PTS)

Deep Vein Thrombosis | Post-thrombotic Syndrome

United States
Guidant Corporation
Boston Scientific Corporation

Completed

Comparison of Right Ventricular Septal and Right Ventricular Apical Pacing in Patients Receiving a CRT-D Device (SEPTAL-CRT)

Ventricular Fibrillation | Ventricular Tachycardia | Systolic Heart Failure

France, Spain
Boston Scientific Corporation

Not yet recruiting

Obsidio™ Conformable Embolic Registry (OCCLUDE)

Hemorrhage | Bleeding | Hypervascular Tumors

Clinical Trials Sponsored by Akston Biosciences Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations